The Oral Microbiome for the Detection of Barretts Esophagus

用于检测 Barretts 食管的口腔微生物组

基本信息

  • 批准号:
    10647639
  • 负责人:
  • 金额:
    $ 39.66万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-06-01 至 2025-05-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY The incidence of esophageal adenocarcinoma (EAC) has risen 10-fold over the past half century and continues to have a dismal prognosis. Barrett’s esophagus (BE) is the precursor lesion to EAC, and patients diagnosed with BE undergo surveillance and endoscopic therapy for early neoplasia. However, more than 90% of EAC patients are never diagnosed with BE beforehand, and widespread upper endoscopy to identify patients with BE is expensive and of questionable value. Thus, there is an urgent need to develop minimally-invasive methods of BE screening that can be easily performed in the primary care setting to allow for efficient and cost-effective interventions to decrease EAC mortality. The esophageal microbiome is heavily influenced by migration of bacteria from the mouth via swallowed secretions. The esophageal microbiome is altered in gastroesophageal reflux and BE, and these changes may therefore reflect changes in the oral microbiome, an easily accessible sampling site. In fact, we have demonstrated that there are marked alterations to the oral microbiome in patients with BE, and a model based on specific taxa can distinguish BE patients with high sensitivity and specificity. We hypothesize that microbiome analysis of saliva can identify patients with BE with high accuracy, thus representing a novel, non-invasive screening test to identify patients at risk for EAC. In the current proposal we aim to validate our preliminary findings in a large endoscopic cohort. We propose to leverage a completed study of patients undergoing a first upper endoscopy with associated saliva samples, as well as patients with suspected early neoplasia (high grade dysplasia or early EAC). In Aim 1, we will determine whether the oral microbiome identifies patients with BE. We hypothesize that a microbiome score based on a model containing relative abundance of Lautropia, Streptococcus, and Enterobacteriaceae identifies patients with and without BE with high accuracy. In Subaim 1a, we will determine whether the oral microbiome in combination with a clinical prediction model (Michigan Barrett’s Esophagus pREdiction Tool; M-BERET) identifies patients with Barrett’s esophagus. As external validation of an oral microbiome signature, we will perform a case-control study using saliva collected as part of a nationwide, primary care-based BE screening study (Subaim 1b). In Aim 2, we will assess whether an oral microbiome signature can identify patients with BE and early neoplasia. In Aim 3, we will conduct a prospective cohort study of 250 patients with and without BE, and collect serial saliva samples to determine whether repeated sampling of the oral microbiome improves identification of patients with BE. We will also assess temporal stability of an oral microbiome signature for the diagnosis of BE. We propose a novel, biologically-based non-endoscopic approach to change the paradigm for EAC prevention. We hope that this will lead to development of a laboratory-based testing strategy that is highly acceptable to patients, is cost-effective, and can be easily translated to the primary care setting.
项目总结

项目成果

期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Clustering of Esophageal Cancer: Differences by Histology.
食管癌的聚集:组织学差异。
  • DOI:
    10.1053/j.gastro.2022.09.003
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    29.4
  • 作者:
    Rubenstein,JoelH
  • 通讯作者:
    Rubenstein,JoelH
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Julian Abrams其他文献

Julian Abrams的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Julian Abrams', 18)}}的其他基金

The Role of Secondary Bile Acids in Gastro-Esophageal Neoplasia
次级胆汁酸在胃食管肿瘤中的作用
  • 批准号:
    10693227
  • 财政年份:
    2022
  • 资助金额:
    $ 39.66万
  • 项目类别:
The Clinical Biospecimen and Research Core
临床生物样本和研究核心
  • 批准号:
    10612956
  • 财政年份:
    2022
  • 资助金额:
    $ 39.66万
  • 项目类别:
The Clinical Biospecimen and Research Core
临床生物样本和研究核心
  • 批准号:
    10443135
  • 财政年份:
    2022
  • 资助金额:
    $ 39.66万
  • 项目类别:
The Role of Secondary Bile Acids in Gastro-Esophageal Neoplasia
次级胆汁酸在胃食管肿瘤中的作用
  • 批准号:
    10506039
  • 财政年份:
    2022
  • 资助金额:
    $ 39.66万
  • 项目类别:
The Role of the Microenvironment in Barrett's Esophagus
微环境在巴雷特食管中的作用
  • 批准号:
    10607819
  • 财政年份:
    2022
  • 资助金额:
    $ 39.66万
  • 项目类别:
The Role of the Microbiome and Notch Signaling in Esophageal Adenocarcinoma
微生物组和 Notch 信号传导在食管腺癌中的作用
  • 批准号:
    10322389
  • 财政年份:
    2021
  • 资助金额:
    $ 39.66万
  • 项目类别:
The Role of the Microbiome and Notch Signaling in Esophageal Adenocarcinoma
微生物组和 Notch 信号传导在食管腺癌中的作用
  • 批准号:
    10747759
  • 财政年份:
    2021
  • 资助金额:
    $ 39.66万
  • 项目类别:
The Role of the Microbiome and Notch Signaling in Esophageal Adenocarcinoma
微生物组和 Notch 信号传导在食管腺癌中的作用
  • 批准号:
    10524194
  • 财政年份:
    2021
  • 资助金额:
    $ 39.66万
  • 项目类别:
The Role of the Microbiome and Notch Signaling in Esophageal Adenocarcinoma
微生物组和 Notch 信号传导在食管腺癌中的作用
  • 批准号:
    10543870
  • 财政年份:
    2021
  • 资助金额:
    $ 39.66万
  • 项目类别:
The Role of the Metaplastic Microenvironment in Barrett's Esophagus
化生微环境在巴雷特食管中的作用
  • 批准号:
    10381174
  • 财政年份:
    2021
  • 资助金额:
    $ 39.66万
  • 项目类别:

相似海外基金

DYNBIOTICS - Understanding the dynamics of antibiotics transport in individual bacteria
DYNBIOTICS - 了解抗生素在单个细菌中转运的动态
  • 批准号:
    EP/Y023528/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.66万
  • 项目类别:
    Research Grant
Engineering Streptomyces bacteria for the sustainable manufacture of antibiotics
工程化链霉菌用于抗生素的可持续生产
  • 批准号:
    BB/Y007611/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.66万
  • 项目类别:
    Research Grant
Hitting bacteria with a Bam: Lectin-Like Antimicrobials as New Antibiotics
用 Bam 击中细菌:凝集素类抗菌剂作为新型抗生素
  • 批准号:
    DP230102150
  • 财政年份:
    2023
  • 资助金额:
    $ 39.66万
  • 项目类别:
    Discovery Projects
“L-form” bacteria: basic science, antibiotics, evolution and biotechnology
L 型细菌:基础科学、抗生素、进化和生物技术
  • 批准号:
    FL210100071
  • 财政年份:
    2022
  • 资助金额:
    $ 39.66万
  • 项目类别:
    Australian Laureate Fellowships
Systematic identification of synthetic interactions in bacteria towards the next-generation of antibiotics
系统鉴定细菌与下一代抗生素的合成相互作用
  • 批准号:
    468567
  • 财政年份:
    2022
  • 资助金额:
    $ 39.66万
  • 项目类别:
    Operating Grants
Repurposing Gram-positive Antibiotics for Gram-Negative Bacteria using Antibiotic Adjuvants
使用抗生素佐剂重新利用革兰氏阳性抗生素治疗革兰氏阴性菌
  • 批准号:
    10708102
  • 财政年份:
    2022
  • 资助金额:
    $ 39.66万
  • 项目类别:
Repurposing Gram-positive Antibiotics for Gram-Negative Bacteria using Antibiotic Adjuvants
使用抗生素佐剂重新利用革兰氏阳性抗生素治疗革兰氏阴性菌
  • 批准号:
    10587015
  • 财政年份:
    2022
  • 资助金额:
    $ 39.66万
  • 项目类别:
Isolation, identification and characterization of potentially novel antibiotics from rhizospheric bacteria without detectable in vitro resistance
从根际细菌中分离、鉴定和表征潜在的新型抗生素,且体外未检测到耐药性
  • 批准号:
    10581945
  • 财政年份:
    2021
  • 资助金额:
    $ 39.66万
  • 项目类别:
Developing novel antibiotics from natural products against resistant bacteria
从天然产物中开发针对耐药细菌的新型抗生素
  • 批准号:
    2599490
  • 财政年份:
    2021
  • 资助金额:
    $ 39.66万
  • 项目类别:
    Studentship
Isolation, identification and characterization of potentially novel antibiotics from rhizospheric bacteria without detectable in vitro resistance
从根际细菌中分离、鉴定和表征潜在的新型抗生素,且体外未检测到耐药性
  • 批准号:
    10358855
  • 财政年份:
    2021
  • 资助金额:
    $ 39.66万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了